Biomedical Nanoparticles: Overview of Their Surface Immune-Compatibility
Source abstract
Abstract
Diagnostic- and therapeutic release-aimed nanoparticles require the highest degree of biocompatibility. Some physical and chemical characteristics of such nanomaterials are often at odds with this requirement. For instance, metals with specific features used as contrast agents in magnetic resonance imaging need particular coatings to improve their blood solubility and increase their biocompatibility. Other examples come from the development of nanocarriers exploiting the different characteristics of two or more materials, i.e., the ability to encapsulate a certain drug by one core-material and the targeting capability of a different coating surface. Furthermore, all these “human-non-self” modifications necessitate proofs of compatibility with the immune system to avoid inflammatory reactions and resultant adverse effects for the patient. In the present review we discuss the molecular interactions and responses of the immune system to the principal nanoparticle surface modifications used in nanomedicine.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for MicroBioRobotics @SSSA, Istituto Italiano di Tecnologia, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy
References (96)
Show source-provided references
1. Highly organized nanostructures for brain drug delivery-new hope or just a fad?
2. Nanoparticles as drug delivery systems10.1016/S1734-1140(12)70901-5 ↗
3. Abbas, A.K., Lichtman, A.H., and Pillai, S. (2009). Cellular and Molecular Immunology, Elsevier. [7th ed.].
4. T lymphocyte trafficking: Molecules and mechanisms10.2741/4111 ↗
5. Natural killer cell biology: An update and future directions10.1016/j.jaci.2013.07.006 ↗
6. Immunosurveillance as a regulator of tissue homeostasis10.1016/j.it.2013.06.005 ↗
7. Chemokines and leukocyte traffic10.1038/ni.f.214 ↗
8. Cxcl12 signaling in the development of the nervous system10.1007/s11481-011-9336-x ↗
9. Evaluation of nanoparticle immunotoxicity10.1038/nnano.2009.175 ↗
10. Materials engineering for immunomodulation10.1038/nature08604 ↗
11. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles10.2147/IJN.S36111 ↗
12. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol)10.1021/la060951b ↗
13. The journey of a drug-carrier in the body: An anatomo-physiological perspective10.1016/j.jconrel.2011.09.098 ↗
14. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats10.2217/17435889.3.5.703 ↗
15. Renal clearance of quantum dots10.1038/nbt1340 ↗
16. Carbon-nanotube shape and individualization critical for renal excretion10.1002/smll.200800323 ↗
17. Complement: A key system for immune surveillance and homeostasis10.1038/ni.1923 ↗
18. Dobrovolskaia, M.A., and McNeil, S.E. (2013). Handbook of Immunological Properties of Engineered Nanomaterials, World Scientific Publishing.10.1142/8390 ↗
19. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption10.1166/jnn.2006.406 ↗
20. Complement: Alive and kicking nanomedicines10.1166/jbn.2009.1045 ↗
21. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: Implications for stealth nanoparticle engineering10.1021/nn101990a ↗
22. Nanocarriers’ entry into the cell: relevance to drug delivery10.1007/s00018-009-0053-z ↗
23. Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization
24. NLRP3 inflammmasome activation induced by engineered nanomaterials10.1002/smll.201201962 ↗
25. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1β production, ROS production and endosomal rupture10.1016/j.biomaterials.2010.05.036 ↗
26. Polymer-coated nanoparticles: A universal tool for biolabelling experiments10.1002/smll.201100608 ↗
27. Evaluation of atherosclerotic lesions using dextran- and mannan-dextran-coated uspio: Mri analysis and pathological findings10.2147/IJN.S29417 ↗
28. Vaccine delivery using nanoparticles10.3389/fcimb.2013.00013 ↗
29. Pegylation of therapeutic proteins10.1002/biot.200900218 ↗
30. Flexible polymerosomes—An alternative vehicle for topical delivery10.1016/j.colsurfb.2009.03.022 ↗
31. Plga-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
32. Design and application of chitosan microspheres as oral and nasal vaccine carriers: An updated review
33. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and rgd-modified alginate10.1016/j.ejps.2011.05.015 ↗
34. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome10.1073/pnas.0804897106 ↗
35. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy10.1016/j.vaccine.2009.03.034 ↗
36. Thiolated pamam dendrimer-coated cdse/znse nanoparticles as protein transfection agents10.1039/b518115a ↗
37. Doxorubicin loading, release, and stability of polyamidoamine dendrimer-coated magnetic nanoparticles10.1002/jps.23524 ↗
38. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system10.1158/0008-5472.CAN-06-4762 ↗
39. Dendronized iron oxide nanoparticles for multimodal imaging10.1016/j.biomaterials.2011.07.026 ↗
40. Dendrimer biocompatibility and toxicity10.1016/j.addr.2005.09.019 ↗
41. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle10.1124/mol.58.5.1100 ↗
42. Effects of n-acetyl-glucosamine-coated glycodendrimers as biological modulators in the b16f10 melanoma model in vivo
43. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation10.1038/nbt995 ↗
44. Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells
45. Sun, I.C., Na, J.H., Jeong, S.Y., Kim, D.E., Kwon, I.C., Choi, K., Ahn, C.H., and Kim, K. (2013). Biocompatible glycol chitosan-coated gold nanoparticles for tumor-targeting ct imaging. Pharm. Res.10.1007/s11095-013-1142-0 ↗
46. Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro10.1016/S0142-9612(97)00017-3 ↗
47. Chitosan-mediated stimulation of macrophage function10.1016/0142-9612(94)90272-0 ↗
48. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration10.1189/jlb.0904541 ↗
49. Chitosan induces different l-arginine metabolic pathways in resting and inflammatory macrophages10.1016/S0006-291X(03)00579-5 ↗
50. Enhanced aggregation of alginate-coated iron oxide (hematite) nanoparticles in the presence of calcium, strontium, and barium cations10.1021/la063744k ↗
51. Alginate-coated chitosan nanogel capacity to modulate the effect of tlr ligands on blood dendritic cells10.1016/j.nano.2013.01.002 ↗
52. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: Effect against breast cancer in mice10.1371/journal.pone.0060190 ↗
53. Stimulation of multiple cytokine production in mice by alginate oligosaccharides following intraperitoneal administration10.1016/j.carres.2007.02.015 ↗
54. Induction of multiple cytokine secretion from raw264.7 cells by alginate oligosaccharides10.1271/bbb.60416 ↗
55. Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines10.1016/j.vaccine.2011.11.057 ↗
56. Dextran and polymer polyethylene glycol (peg) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2d and 3d cell culture10.3390/ijms13055554 ↗
57. Osborne, E.A., Atkins, T.M., Gilbert, D.A., Kauzlarich, S.M., Liu, K., and Louie, A.Y. (2013). Rapid microwave-assisted synthesis of dextran-coated iron oxide nanoparticles for magnetic resonance imaging. Nanotechnology, 23.10.1088/0957-4484/23/21/215602 ↗
58. The effective nuclear delivery of doxorubicin from dextran-coated gold nanoparticles larger than nuclear pores10.1016/j.biomaterials.2013.01.076 ↗
59. Characterization of chitosan-carboxymethyl dextran nanoparticles as a drug carrier and as a stimulator of mouse splenocytes10.1163/092050611X582849 ↗
60. Yuryev, V.P., Tomasik, P., and Bertoft, E. (2007). Starch: Achievements in Understanding of Structure and Functionality, Nova Science Publishers.
61. Nanoparticles and the skin—applications and limitations10.3109/02652048.2011.599440 ↗
62. Spherex (degradable starch microspheres) chemo-occlusion—Enhancement of tumor drug concentration and therapeutic efficacy: An overview
63. Bactericidal activity of starch-encapsulated gold nanoparticles10.2741/4158 ↗
64. Magnetic brain tumor targeting and biodistribution of long-circulating peg-modified, cross-linked starch-coated iron oxide nanoparticles10.1016/j.biomaterials.2011.05.024 ↗
65. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting10.1016/j.biomaterials.2010.11.040 ↗
66. Silica-based nanoprobes for biomedical imaging and theranostic applications10.1039/c2cs15229k ↗
67. The biocompatibility of amino functionalized CdSe/Zn quantum-dot-doped SiO2 nanoparticles with primary neural cells and their gene carrying performance10.1016/j.biomaterials.2010.04.063 ↗
68. SiO2 nanoparticles biocompatibility and their potential for gene delivery and silencing10.1039/C1NR11269D ↗
69. Biocompatibility of mesoporous silica nanoparticles10.1021/tx300166u ↗
70. Amorphous silica nanoparticles promote monocyte adhesion to human endothelial cells: Size-dependent effect10.1002/smll.201201033 ↗
71. The toxicological mode of action and the safety of synthetic amorphous silica—a nanostructured material10.1016/j.tox.2012.02.001 ↗
72. Nanoparticles in targeted cancer therapy: Mesoporous silica nanoparticles entering preclinical development stage10.2217/nnm.11.166 ↗
73. Synthesis and characterization of large colloidal cobalt particles10.1021/la0526885 ↗
74. Synthesis of core-shell gold coated magnetic nanoparticles and their interaction with thiolated DNA10.1039/c0nr00621a ↗
75. Novel superparamagnetic core(shell) nanoparticles for magnetic targeted drug delivery and hyperthermia treatment10.1109/TMAG.2005.854805 ↗
76. Laser and radiofrequency-induced hyperthermia treatment via gold-coated magnetic nanocomposites10.2147/IJN.S23952 ↗
77. Magnetic nanoparticle-induced hyperthermia treatment under magnetic resonance imaging10.1016/j.mri.2010.08.010 ↗
78. Hashimoto, M., Toshima, H., Yonezawa, T., Kawai, K., Narushima, T., Kaga, M., and Endo, K. (2013). Responses of raw264.7 macrophages to water-dispersible gold and silver nanoparticles stabilized by metal-carbon sigma-bonds. J. Biomed. Mater. Res. A, in press.10.1002/jbm.a.34854 ↗
79. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells10.1021/nl052396o ↗
80. Titanium oxide shell coatings decrease the cytotoxicity of zno nanoparticles10.1021/tx1001892 ↗
81. Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells10.1158/0008-5472.CAN-11-2890 ↗
82. Nano-sized cosmetic formulations or solid nanoparticles in sunscreens: A risk to human health?10.1007/s00204-012-0831-5 ↗
83. The potential health risk of titania nanoparticles
84. Genotoxicity of metal nanoparticles: Focus on in vivo studies10.2478/10004-1254-63-2012-2213 ↗
85. Toxicological effects of titanium dioxide nanoparticles: A review of in vitro mammalian studies
86. TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils10.1016/j.toxlet.2013.05.010 ↗
87. Structure and function of the blood-brain barrier10.1016/j.nbd.2009.07.030 ↗
88. Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the cns10.4155/tde.12.55 ↗
89. Polymeric nanoparticles for the drug delivery to the central nervous system10.1517/17425247.5.2.155 ↗
90. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging10.1186/1743-8977-7-3 ↗
91. Microglia: Scapegoat, saboteur, or something else?10.1126/science.1227901 ↗
92. The effect of lipid nanoparticle pegylation on neuroinflammatory response in mouse brain10.1016/j.biomaterials.2013.07.009 ↗
93. Water dispersal and functionalization of hydrophobic iron oxide nanoparticles with lipid-modified poly(amidoamine) dendrimers10.1021/la400791a ↗
94. Surface functionalisation regulates polyamidoamine dendrimer toxicity on blood-brain barrier cells and the modulation of key inflammatory receptors on microglia10.3109/17435390.2013.765054 ↗
95. Kannan, S., Dai, H., Navath, R.S., Balakrishnan, B., Jyoti, A., Janisse, J., Romero, R., and Kannan, R.M. (2012). Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci. Transl. Med., 4.10.1126/scitranslmed.3003162 ↗
96. Oostingh, G.J., Casals, E., Italiani, P., Colognato, R., Stritzinger, R., Ponti, J., Pfaller, T., Kohl, Y., Ooms, D., and Favilli, F. (2011). Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part. Fibre Toxicol., 8.10.1186/1743-8977-8-8 ↗